|
JO3474B1
(ar)
|
2014-08-29 |
2020-07-05 |
Amgen Inc |
مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
|
|
US11306107B2
(en)
|
2016-02-25 |
2022-04-19 |
Amgen Inc. |
Compounds that inhibit MCL-1 protein
|
|
WO2017197046A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
C3-carbon linked glutarimide degronimers for target protein degradation
|
|
ES2989988T3
(es)
|
2016-05-10 |
2024-11-28 |
C4 Therapeutics Inc |
Degronímeros heterorocíclicos para la degradación de proteínas diana
|
|
CN109562113A
(zh)
|
2016-05-10 |
2019-04-02 |
C4医药公司 |
用于靶蛋白降解的螺环降解决定子体
|
|
WO2017197051A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Amine-linked c3-glutarimide degronimers for target protein degradation
|
|
UY37342A
(es)
|
2016-07-22 |
2018-01-31 |
Servier Lab |
Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos
|
|
JP6453507B2
(ja)
|
2017-03-30 |
2019-01-16 |
アムジエン・インコーポレーテツド |
Ｍｃｌ−１タンパク質を阻害する化合物
|
|
CN110769822A
(zh)
|
2017-06-20 |
2020-02-07 |
C4医药公司 |
用于蛋白降解的n/o-连接的降解决定子和降解决定子体
|
|
EP3668502A4
(en)
*
|
2017-08-15 |
2021-01-13 |
AbbVie Inc. |
MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE
|
|
KR20200041942A
(ko)
*
|
2017-08-15 |
2020-04-22 |
애브비 인코포레이티드 |
거대환식 mcl-1 저해제 및 이의 용도
|
|
ES3036998T3
(en)
|
2017-08-18 |
2025-09-26 |
Amgen Inc |
Compounds that inhibit mcl-1 protein
|
|
US11279712B2
(en)
|
2017-08-29 |
2022-03-22 |
Amgen Inc. |
Macrocyclic compounds that inhibit MCL-1 protein
|
|
MA54985A
(fr)
|
2018-03-05 |
2021-12-29 |
Amgen Inc |
Pharmacophores d'acide alpha-hydroxy phénylacétique ou antagonistes de la protéine bio-isostère mcl-1
|
|
US10703733B2
(en)
*
|
2018-05-14 |
2020-07-07 |
Gilead Sciences, Inc. |
MCL-1 inhibitors
|
|
CA3118919A1
(en)
*
|
2018-11-09 |
2020-05-14 |
Prelude Therapeutics, Incorporated |
Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein
|
|
CN120698983A
(zh)
|
2018-12-20 |
2025-09-26 |
C4医药公司 |
靶向蛋白降解
|
|
TWI745836B
(zh)
*
|
2019-01-18 |
2021-11-11 |
大陸商蘇州亞盛藥業有限公司 |
作為mcl-1抑製劑的大螺環醚
|
|
PY2020118A
(es)
|
2019-05-20 |
2022-10-27 |
Servier Lab |
Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso
|
|
TWI826690B
(zh)
|
2019-05-23 |
2023-12-21 |
美商基利科學股份有限公司 |
經取代之烯吲哚酮化物及其用途
|
|
ES2975083T3
(es)
*
|
2019-06-21 |
2024-07-03 |
Janssen Pharmaceutica Nv |
Inhibidores macrocíclicos de MCL-1
|
|
MX2021015452A
(es)
|
2019-06-25 |
2022-02-11 |
Gilead Sciences Inc |
Proteinas de fusion flt3l-fc y metodos de uso.
|
|
MX2022000390A
(es)
|
2019-07-09 |
2022-02-10 |
Janssen Pharmaceutica Nv |
Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
|
|
EP3771469A1
(en)
*
|
2019-07-30 |
2021-02-03 |
Amgen, Inc |
Formulations and dosages for administering a compound that inhibits mcl1 protein
|
|
CN112479876B
(zh)
*
|
2019-09-12 |
2023-07-21 |
苏州亚盛药业有限公司 |
氧氮杂环庚烷类螺环化合物、中间体及其制备方法
|
|
MX2022004370A
(es)
|
2019-10-18 |
2022-05-06 |
Forty Seven Inc |
Terapias de combinacion para tratar sindromes mielodisplasicos y leucemia mieloide aguda.
|
|
WO2021087064A1
(en)
|
2019-10-31 |
2021-05-06 |
Forty Seven, Inc. |
Anti-cd47 and anti-cd20 based treatment of blood cancer
|
|
EP4054719B1
(en)
|
2019-11-04 |
2026-02-11 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
JP7823816B2
(ja)
*
|
2019-11-04 |
2026-03-04 |
レヴォリューション・メディスンズ，インコーポレイテッド |
Ｒａｓ阻害剤
|
|
TWI778443B
(zh)
*
|
2019-11-12 |
2022-09-21 |
美商基利科學股份有限公司 |
Mcl1抑制劑
|
|
US11325891B2
(en)
*
|
2019-11-26 |
2022-05-10 |
Gilead Sciences, Inc. |
Processes and intermediates for preparing MCL1 inhibitors
|
|
JP7711068B2
(ja)
|
2019-12-24 |
2025-07-22 |
カルナバイオサイエンス株式会社 |
ジアシルグリセロールキナーゼ調節化合物
|
|
IL295023A
(en)
|
2020-02-14 |
2022-09-01 |
Jounce Therapeutics Inc |
Antibodies and fusion proteins that bind to ccr8 and their uses
|
|
WO2021165370A1
(en)
*
|
2020-02-21 |
2021-08-26 |
Janssen Pharmaceutica Nv |
Macrocyclic indole derivatives as inhibitors of mcl-1
|
|
JP2021161114A
(ja)
*
|
2020-03-31 |
2021-10-11 |
アムジエン・インコーポレーテツド |
Ｍｃｌ−１化合物のメチル化
|
|
US20230212191A1
(en)
*
|
2020-04-16 |
2023-07-06 |
Prelude Therapeutics, Incorporated |
Spiro-sulfonimidamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein
|
|
CR20220547A
(es)
|
2020-05-01 |
2022-12-15 |
Gilead Sciences Inc |
Compuestos de 2,4-dioxopirimidina inhibidores de cd73
|
|
WO2021225833A1
(en)
|
2020-05-06 |
2021-11-11 |
Amgen Inc. |
Synthesis of sulfonamide intermediates
|
|
WO2021225835A1
(en)
*
|
2020-05-06 |
2021-11-11 |
Amgen Inc. |
Synthesis of vinylic alcohol intermediates
|
|
TWI827924B
(zh)
*
|
2020-05-06 |
2024-01-01 |
美商安進公司 |
大環Mcl-1抑制劑中間體的閉環合成
|
|
TWI867217B
(zh)
*
|
2020-05-06 |
2024-12-21 |
美商安進公司 |
乙烯基環丁基中間體之合成
|
|
IL297520B2
(en)
*
|
2020-05-06 |
2025-11-01 |
Amgen Inc |
Synthesis of vinylic protected alcohol intermediates
|
|
WO2021250102A1
(en)
|
2020-06-10 |
2021-12-16 |
Janssen Pharmaceutica Nv |
Macrocyclic 2-amino-3-fluoro-but-3-enamides as inhibitors of mcl-1
|
|
CA3193132A1
(en)
*
|
2020-09-03 |
2022-03-10 |
Amgen Inc. |
Diol desymmetrization by nucleophilic aromatic substitution
|
|
CR20230165A
(es)
|
2020-09-15 |
2023-06-02 |
Revolution Medicines Inc |
Derivados indólicos como inhibidores de ras en el tratamiento del cáncer
|
|
US12202782B2
(en)
*
|
2020-11-19 |
2025-01-21 |
Gilead Sciences, Inc. |
Processes and intermediates for preparing MCL1 inhibitors
|
|
CN117136076A
(zh)
|
2020-11-24 |
2023-11-28 |
诺华股份有限公司 |
Mcl-1抑制剂抗体药物缀合物和使用方法
|
|
BR112023010228A2
(pt)
*
|
2020-11-25 |
2023-10-17 |
Amgen Inc |
Alquenilação enantiosseletiva de aldeídos
|
|
WO2022122667A1
(en)
|
2020-12-07 |
2022-06-16 |
Cellestia Biotech Ag |
Pharmaceutical combinations for treating cancer
|
|
EP4008324A1
(en)
|
2020-12-07 |
2022-06-08 |
Cellestia Biotech AG |
Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer
|
|
JP2023554070A
(ja)
|
2020-12-17 |
2023-12-26 |
ヤンセン ファーマシューティカ エヌ．ベー． |
Ｍｃｌ－１の阻害剤としての分岐３－フルオロ－ブタ－３－エナミド
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
ES3017082T3
(en)
|
2021-04-26 |
2025-05-12 |
Janssen Pharmaceutica Nv |
Macrocyclic 2-allyltetrahydrofurans as inhibitors of mcl-1
|
|
CR20230558A
(es)
|
2021-05-05 |
2024-01-24 |
Revolution Medicines Inc |
Inhibidores de ras para el tratamiento del cáncer
|
|
TW202313094A
(zh)
|
2021-05-18 |
2023-04-01 |
美商基利科學股份有限公司 |
使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
|
|
EP4351564A1
(en)
|
2021-06-11 |
2024-04-17 |
Gilead Sciences, Inc. |
Combination mcl-1 inhibitors with anti-cancer agents
|
|
CA3222752A1
(en)
|
2021-06-11 |
2022-12-15 |
Gilead Sciences, Inc. |
Combination mcl-1 inhibitors with anti-body drug conjugates
|
|
AU2022298639C1
(en)
|
2021-06-23 |
2025-07-17 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
AU2022299051B2
(en)
|
2021-06-23 |
2025-03-13 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
KR20240025616A
(ko)
|
2021-06-23 |
2024-02-27 |
길리애드 사이언시즈, 인코포레이티드 |
다이아실글리세롤 키나제 조절 화합물
|
|
KR20240005901A
(ko)
|
2021-06-23 |
2024-01-12 |
길리애드 사이언시즈, 인코포레이티드 |
디아실글리세롤 키나제 조절 화합물
|
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
|
JP2024539252A
(ja)
|
2021-10-28 |
2024-10-28 |
ギリアード サイエンシーズ， インコーポレイテッド |
ピリジジン－３（２ｈ）－オン誘導体
|
|
CA3235986A1
(en)
|
2021-10-29 |
2023-05-04 |
Gilead Science, Inc. |
Cd73 compounds
|
|
US20250051359A1
(en)
|
2021-11-16 |
2025-02-13 |
Janssen Pharmaceutica Nv |
Macrocyclic 2-amino-but-3-enamides as inhibitors of mcl-1
|
|
US20230203202A1
(en)
|
2021-12-08 |
2023-06-29 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and 5t4
|
|
WO2023107954A1
(en)
|
2021-12-08 |
2023-06-15 |
Dragonfly Therapeutics, Inc. |
Antibodies targeting 5t4 and uses thereof
|
|
EP4667056A1
(en)
|
2021-12-22 |
2025-12-24 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
EP4452414A2
(en)
|
2021-12-22 |
2024-10-30 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
LT4245756T
(lt)
|
2022-03-17 |
2024-11-25 |
Gilead Sciences, Inc. |
Ikaros cinko pirštų šeimos skaidymo medžiagos ir jų panaudojimas
|
|
AU2023240346A1
(en)
|
2022-03-24 |
2024-09-19 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
|
WO2023196361A1
(en)
|
2022-04-05 |
2023-10-12 |
Amgen Inc. |
Amorphous and crystalline forms of mci-1 antagonists
|
|
AU2023249146A1
(en)
|
2022-04-05 |
2024-10-10 |
Amgen Inc. |
Salt forms and solvates of mci-1 antagonists
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
US20230374036A1
(en)
|
2022-04-21 |
2023-11-23 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20250387504A1
(en)
|
2022-05-20 |
2025-12-25 |
Novartis Ag |
Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
|
|
IL317958A
(en)
|
2022-07-01 |
2025-02-01 |
Gilead Sciences Inc |
CD73 compounds
|
|
WO2024064668A1
(en)
|
2022-09-21 |
2024-03-28 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
EP4638436A1
(en)
|
2022-12-22 |
2025-10-29 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
EP4695260A1
(en)
|
2023-04-11 |
2026-02-18 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
KR20250175331A
(ko)
|
2023-04-21 |
2025-12-16 |
길리애드 사이언시즈, 인코포레이티드 |
Prmt5 억제제 및 이의 용도
|
|
AU2024306338A1
(en)
|
2023-06-30 |
2026-01-08 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
AU2024297978A1
(en)
|
2023-07-26 |
2026-02-05 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
AU2024300557A1
(en)
|
2023-07-26 |
2026-02-05 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
EP4516807A1
(en)
|
2023-08-28 |
2025-03-05 |
Consorcio Centro de Investigación Biomédica en Red |
Compositions for use in a method of providing improved hematopoietic stem cell engraftment
|
|
WO2025054530A1
(en)
|
2023-09-08 |
2025-03-13 |
Gilead Sciences, Inc. |
Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
|
|
US20250101042A1
(en)
|
2023-09-08 |
2025-03-27 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20250154172A1
(en)
|
2023-11-03 |
2025-05-15 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
TW202540185A
(zh)
|
2023-11-22 |
2025-10-16 |
法商施維雅藥廠 |
抗cd74抗體藥物結合物及其使用方法
|
|
WO2025111431A1
(en)
|
2023-11-22 |
2025-05-30 |
Les Laboratoires Servier |
Anti-cd7 antibody-drug conjugates and methods of use thereof
|
|
WO2025126157A1
(en)
|
2023-12-15 |
2025-06-19 |
Advesya |
Anti-il-1rap binding domains and antibody-drug conjugates thereof
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025245003A1
(en)
|
2024-05-21 |
2025-11-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2026039365A1
(en)
|
2024-08-12 |
2026-02-19 |
Gilead Sciences, Inc. |
Kras modulating compounds
|